Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
BrightPath Biotherapeutics, Apr-Jun (1Q) Net Income Loss Narrows
U.S. FDA Orphan Drug Designation Granted to BP2202 for the Treatment of Multiple Myeloma
BrightPath Presented Data on Bispecific Antibody BP1212 for Cancer Therapy at IRCI 2025
Brightpath to Present Data on Bispecific Antibody BP1212 for Cancer Immunotherapy at IRCI 2025
BrightPath Biotherapeutics, Continue Net Income Turns to Loss
BrightPath Biotherapeutics, The Current Fiscal Year Net Income Loss Widened in Downward Revision
BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Narrows
BrightPath Biotherapeutics Co., Ltd., First Half Net Income Loss Narrows, July-September Net Income Loss Narrows